retatrutide fatty liver disease Triple hormone receptor agonist for metabolic dysfunction-associated steatotic disease: a randomized phase 2a trial Retatrutide Significantly Reduces Visceral Fat

Thence, we tested mainly the following hypotheses: 1

This information is for educational purposes and is not medical advice

They'll serve different niches: CagriSema Will Dominate: Patients familiar with Wegovy brand Those wanting proven semaglutide component People with type 2 diabetes (strong REIMAGINE data) Earlier availability (mid-2027) Retatrutide Will Dominate: Patients needing maximum weight loss (BMI 40) Those with multiple complications (OA + OSA + obesity) People who failed CagriSema Willingness to wait for highest efficacy Tirzepatide (Zepbound) Will Remain Relevant: Already available NOW Proven safety with 22.5% weight loss Lower cost than either new option Established insurance coverage The High-Dose CagriSema Wildcard Novo Nordisk announced plans for CagriSema 2.4mg/7.2mg trials starting late 2026tripling the cagrilintide dose

25 As an endocrine hormone, GLP-1 is secreted by enteroendocrine L-cells in the distal jejunum, ileum, and colon in response to food intake and neuroendocrine signals